Jacobio Pharmaceuticals Group saw the highest growth of 3.49% in patent filings and 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Jacobio Pharmaceuticals Group’s patent filings and grants. Buy the databook here.
Jacobio Pharmaceuticals Group has been focused on protecting inventions in European Patent Office(EPO) with four publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 27% of filings. The European Patent Office(EPO), United States(US), South Korea(KR), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where Jacobio Pharmaceuticals Group is filings its patents. Among the top granted patent authorities, Jacobio Pharmaceuticals Group has 100% of its grants in Australia(AU).
Roche could be the strongest competitor for Jacobio Pharmaceuticals Group
Patents related to rare diseases lead Jacobio Pharmaceuticals Group's portfolio
Jacobio Pharmaceuticals Group has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Lung cancer related patents lead Jacobio Pharmaceuticals Group portfolio followed by pancreatic cancer, and colorectal tumor
Jacobio Pharmaceuticals Group has highest number of patents in lung cancer followed by pancreatic cancer, colorectal tumor, endometrial cancer, and non-small cell lung cancer.
For comprehensive analysis of Jacobio Pharmaceuticals Group's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.